Olaparib for the treatment of breast cancer

Research output: Contribution to journalReview articlepeer-review


INTRODUCTION: Mutations in BRCA1 and BRCA2 genes account for around 2-3% of breast cancer events and more than 10% of triple negative breast cancers. Olaparib (Lynparza®), an orally administered PARP inhibitor, demonstrated clinical benefit in a phase III trial for mutated BRCA-positive HER2 negative metastatic breast cancer. Areas covered: This review gives an overview of available preclinical and clinical data regarding olaparib, including its chemistry, mechanism of action, pharmacokinetics and pharmacodynamics, and evidence supporting antitumor efficacy and safety profile in breast cancer patients. Expert commentary: Olaparib improves progression-free survival in germline BRCA mutated HER2 negative metastatic breast cancer patients as compared to standard chemotherapy, with a manageable toxicity profile. Efficacy is of clinical relevance especially in the context of triple negative breast cancer. However, several aspects, such as sequencing or combination of these agents with other anticancer agents and identification of appropriate biomarkers, still need to be clearly defined.

Original languageEnglish
Pages (from-to)519-530
Number of pages12
JournalExpert Review of Anticancer Therapy
Issue number6
Publication statusPublished - Jun 2018


  • Antineoplastic Agents/adverse effects
  • BRCA1 Protein/genetics
  • BRCA2 Protein/genetics
  • Breast Neoplasms/drug therapy
  • Disease-Free Survival
  • Female
  • Humans
  • Phthalazines/adverse effects
  • Piperazines/adverse effects
  • Poly(ADP-ribose) Polymerase Inhibitors/adverse effects
  • Receptor, ErbB-2/metabolism


Dive into the research topics of 'Olaparib for the treatment of breast cancer'. Together they form a unique fingerprint.

Cite this